Immune Regulation News Volume 9.07 | Feb 24 2017

TOP STORY

The Role of Alternative Polyadenylation in the Antiviral Innate Immune Response

Scientists showed genome-wide poly(A) sites switch and average 3′ UTR length shortens gradually in response to vesicular stomatitis virus infection in macrophages. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

Tumor and Host Cell PD-L1 Is Required to Mediate Suppression of Anti-Tumor Immunity in Mice

Using genetic deletion in preclinical mouse models, researchers showed that PD-L1 from disparate cellular sources, including tumor cells, myeloid or other immune cells can similarly modulate the degree of cytotoxic T-cell function and activity in the tumor microenvironment. [Nat Commun] Full Article

PLCε1 Regulates SDF-1α–Induced Lymphocyte Adhesion and Migration to Sites of Inflammation

Scientists identified that phospholipase Cε 1 (PLCε1) was necessary for stromal cell-derived factor 1 alpha (SDF-1α)-induced adhesion using shear stress, cell morphology alterations, and crawling on intercellular adhesion molecule 1–expressing cells. [Proc Natl Acad Sci USA] Abstract

Gut Memories Do Not Fade: Epigenetic Regulation of Lasting Gut Homing Receptor Expression in CD4⁺ Memory T Cells

The authors demonstrated that α₄β₇ expression in murine CD4⁺ memory T cells is imprinted and remains stable in the absence of the inducing factor retinoic acid or other stimuli from mucosal environments. [Mucosal Immunol] Abstract

Cbx3/HP1γ Deficiency Confers Enhanced Tumor-Killing Capacity on CD8⁺ T Cells

In tumors obtained from Cbx3/HP1γ-insufficient mice or wild type mice treated with Cbx3/HP1γ-insufficient CD8⁺ T cells, there is an increase of CD8⁺ effector T cells expressing the stimulatory receptor Klrk1/NKG2D, a decrease in CD4⁺ CD25⁺ FOXP3⁺ regulatory T cells as well as CD25⁺ CD4⁺ T cells expressing the inhibitory receptor CTLA4. [Sci Rep] Full Article

NK1.1⁻ CD4⁺ NKG2D⁺ T Cells Suppress DSS-Induced Colitis in Mice through Production of TGF-β

Murine CD4⁺ NKG2D⁺ T cells were classified into NK1.1⁻ CD4⁺ NKG2D⁺ and NK1.1⁺ CD4⁺ NKG2D⁺ subpopulations. The frequency of NK1.1⁻ CD4⁺ NKG2D⁺ cells decreased in inflamed colons, whereas more NK1.1⁺ CD4⁺ NKG2D⁺ cells infiltrated into colons of mice with DSS-induced colitis. [J Cell Mol Med] Full Article

Silencing c-Rel in Macrophages Dampens Th1 and Th17 Immune Responses and Alleviates Experimental Autoimmune Encephalomyelitis in Mice

Investigators successfully silenced the expression of the transcription factor c-Rel in macrophages of mice with experimental autoimmune encephalomyelitis (including those infiltrating the central nervous system) using chemically modified c-Rel-specific siRNAs delivered by nanoparticles. [Immunol Cell Biol] Abstract

Priming with High and Low Respiratory Allergen Dose Induces Differential CD4⁺ Th2 Cells and IgE/IgG1 Antibody Responses in Mice

Researchers investigated the role of dose in the immune response to an inhaled respiratory allergen. They observed the effect of priming dose on the allergic response in mice intranasally immunized with low and high dose of Blomia tropicalis extract and sacrificed one day after the last challenge. [Immunology] Abstract

Differential Regulation of C5a Receptor 1 in Innate Immune Cells during the Allergic Asthma Effector Phase

Investigators used this reporter strain to monitor C5a receptor 1 (C5aR1) expression in airway, pulmonary and lymph node cells during the effector phase of OVA-driven allergic asthma. C5aR1 reporter and wildtype mice developed a similar allergic phenotype with comparable airway resistance, mucus production, eosinophilic/neutrophilic airway inflammation and Th2/Th17 cytokine production. [PLoS One] Full Article

Subscribe to our sister publications: Human Immunology News & Immunology of Infectious Disease News.

SOCS: Potential Immune Checkpoint Molecules for Cancer Immunotherapy

The authors summarize recent progress on CIS, suppressor of cytokine signaling (SOCS)1, and SOCS3 in terms of their anti-tumor immunity and potential applications. [Cancer Sci] Abstract

Visit our reviews page to see a complete list of reviews in the immune regulation research field.

MabSpace Biosciences to Present Preclinical Data on Second Generation PD-L1 Antibody with pH-Dependent Antigen Binding Property

MabSpace Biosciences announced that the preclinical data for its lead program MSB2311, a second generation humanized PD-L1 blocking antibody with a unique pH-dependent antigen binding property, will be presented. [Press release from MabSpace Biosciences (Business Wire, Inc.) discussing research presented at the 2017 Inaugural American Society of Clinical Oncology (ASCO)-Society for Immunotherapy of Cancer (SITC) Annual Meeting, Orlando] Press Release

OncoSec Announces Positive Phase II Data Demonstrating Company’s ImmunoPulse^® IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients

OncoSec Medical Incorporated reported new positive clinical data from a Phase II Investigator Sponsored Trial assessing the combination of OncoSec’s investigational intratumoral therapy, ImmunoPulse^® IL-12, and the approved anti-PD-1 therapy, in patients with unresectable metastatic melanoma. [OncoSec Medical Incorporated] Press Release

ImmusanT Announces Completion of Phase Ib Clinical Trial of Nexvax2^® for the Treatment of Celiac Disease

ImmusanT, Inc. announced the completion of a Phase Ib clinical trial evaluating the safety and tolerability of Nexvax2 in celiac disease. [ImmusanT, Inc.] Press Release

REVLIMID^® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation

Celgene International Sàrl announced that the European Commission has approved REVLIMID^® as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. [Celgene International Sàrl] Press Release

DARZALEX^® (Daratumumab) Receives Positive CHMP Opinion for the Treatment of Multiple Myeloma in Patients Who Have Received At Least One Prior Therapy

Janssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended broadening the existing marketing authorisation for DARZALEX^®. [Janssen-Cilag International NV (Business Wire, Inc.)] Press Release

MIODx Licenses Key Immunotherapy Technologies from UCSF

MIODx announced that it has signed an exclusive license for two key immunotherapy technologies from the University of California, San Francisco (UCSF). [MIODx (PR Newswire Association LLC.)] Press Release

Updated: Will They or Won’t They? What Science Groups Are Saying About Joining the March for Science

The March for Science is creating a buzz in the scientific community. The march arose as a grassroots reaction to concerns about the conduct of science under President Donald Trump. And it has spurred debate over whether it will help boost public support for research, or make scientists look like another special-interest group, adding to political polarization. [Science Insider] Editorial

Firing of Veteran NIH Scientist Prompts Protests over Publication Ban

At least two dozen junior and senior researchers are stuck in scientific limbo after being barred from publishing data collected over a 25-year period at a National Institutes of Health (NIH) lab. The unusual ban follows the firing last summer of veteran neurologist Allen Braun by the National Institute on Deafness and Other Communication Disorders for what many scientists have told Science are relatively minor, if widespread, violations of his lab’s experimental protocol. [ScienceInsider] Editorial

Why British Universities Are Unlikely to Accept Invitation to Set Up Campuses in France

A consortium of academic institutes near Paris is hoping to lure British universities to create research campuses in France, dangling as bait the possibility of access to European Union research funds after Brexit. [Nature News] Editorial

NEW Keystone Symposium: Mononuclear Phagocytes in Health, Immune Defense and Disease
April 30-May 4, 2017
Austin, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Researcher – Development of Immune System (Lund University)

Research Technologist – Cell Separation & Immunology (STEMCELL Technologies, Inc.)

Research Investigator – Immuno-Oncology (Bristol-Meyers Squibb)

Associate/Full Professor – Immunobioengineering (University of Toronto)

Research Assistant/Associate – Tuning the Immune Response in Tuberculosis (University College London)

Postdoctoral Position – Immunology (Boston University School of Medicine & Boston Medical Center)

Scientist – Immunology (Moderna Therapeutics)

Postdoctoral Fellow – Immunology (Institute of Molecular and Cell Biology)

Scientist Positions – Immunology (New York Blood Center)

Senior Scientist – (Immatics Biotechnologies GmbH)

Assistant Associate or Full Member – Cancer Immunology (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Molecular Immunology (University of California, San Diego)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or suggestions? Submit your feedback here.